Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41714
Title: Eculizumab in secondary atypical haemolytic uraemic syndrome.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2017
Citation: Nephrol. Dial. Transplant..2017 03;(32)3:466-474
Abstract: Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.
PMID: 28339660
URI: https://hdl.handle.net/20.500.12530/41714
Rights: openAccess
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos
Hospitales > H. U. Puerta de Hierro Majadahonda > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Puerta de Hierro-Segovia de Arana > Artículos

Files in This Item:
File Description SizeFormat 
PMC5410989.pdf891.17 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.